TradingKey

Más Datos de LENZ Therapeutics Inc Compañía

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

Información de la empresa

Símbolo de cotizaciónLENZ

Nombre de la empresaLENZ Therapeutics Inc

Fecha de salida a bolsaJun 25, 2021

Director ejecutivoMr. Evert (Eef) Schimmelpennink

Número de empleados42

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 25

Dirección- -

Ciudad- -

Bolsa de valoresNASDAQ Global Select Consolidated

País- -

Código postal- -

Teléfono- -

Sitio Web- -

Símbolo de cotizaciónLENZ

Fecha de salida a bolsaJun 25, 2021

Director ejecutivoMr. Evert (Eef) Schimmelpennink

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Marc Odrich

Chief Medical Officer

99.60K

--

Shawn Olsson

Chief Commercial Officer

4.73K

+42.00%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

3.19K

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Ms. Shelley B. Thunen

Independent Director

--

James Mccollum

Independent Director

--

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

--

Jeff W. George

Independent Chairman of the Board

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Marc Odrich

Chief Medical Officer

99.60K

--

Shawn Olsson

Chief Commercial Officer

4.73K

+42.00%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

3.19K

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Ms. Shelley B. Thunen

Independent Director

--

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: vie., 16 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

RA Capital Management, LP

14.65%

Alpha Wave Global, LP

12.66%

Versant Ventures

12.15%

Ridgeback Capital Management, L.P.

6.84%

Point72 Asset Management, L.P.

6.60%

Other

47.09%

Accionistas

Proporción

RA Capital Management, LP

14.65%

Alpha Wave Global, LP

12.66%

Versant Ventures

12.15%

Ridgeback Capital Management, L.P.

6.84%

Point72 Asset Management, L.P.

6.60%

Other

47.09%

Tipos de accionistas

Accionistas

Proporción

Venture Capital

41.87%

Hedge Fund

24.75%

Investment Advisor

21.00%

Investment Advisor/Hedge Fund

11.47%

Individual Investor

2.76%

Research Firm

0.79%

Bank and Trust

0.13%

Pension Fund

0.05%

Insurance Company

0.02%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

244

29.26M

103.53%

-770.18K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

2023Q3

200

7.54M

90.13%

-2.49M

2023Q2

212

7.64M

91.96%

-2.29M

2023Q1

205

7.41M

89.08%

-2.37M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

RA Capital Management, LP

4.18M

14.85%

--

May 07, 2025

Alpha Wave Global, LP

3.61M

12.83%

--

Apr 14, 2025

Versant Ventures

3.66M

12.99%

-884.80K

-19.48%

Jun 27, 2025

Ridgeback Capital Management, L.P.

1.95M

6.93%

--

Apr 14, 2025

Point72 Asset Management, L.P.

1.88M

6.69%

+1.03M

+120.91%

Apr 14, 2025

Paradigm BioCapital Advisors LP

1.42M

5.04%

-92.10K

-6.09%

Apr 14, 2025

The Vanguard Group, Inc.

1.20M

4.25%

+21.02K

+1.79%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.05M

3.73%

-14.66K

-1.38%

Mar 31, 2025

72 Investment Holdings, LLC

1.02M

3.62%

--

Mar 31, 2025

Sectoral Asset Management Inc.

977.25K

3.47%

--

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

Harbor Health Care ETF

0.91%

Virtus LifeSci Biotech Clinical Trials ETF

0.89%

SPDR S&P Pharmaceuticals ETF

0.83%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.59%

iShares Micro-Cap ETF

0.12%

Invesco Nasdaq Biotechnology ETF

0.09%

ProShares Ultra Nasdaq Biotechnology

0.09%

iShares Biotechnology ETF

0.07%

Avantis US Small Cap Equity ETF

0.05%

Vanguard US Momentum Factor ETF

0.05%

Harbor Health Care ETF

Proporción0.91%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.89%

SPDR S&P Pharmaceuticals ETF

Proporción0.83%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción0.59%

iShares Micro-Cap ETF

Proporción0.12%

Invesco Nasdaq Biotechnology ETF

Proporción0.09%

ProShares Ultra Nasdaq Biotechnology

Proporción0.09%

iShares Biotechnology ETF

Proporción0.07%

Avantis US Small Cap Equity ETF

Proporción0.05%

Vanguard US Momentum Factor ETF

Proporción0.05%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Mar 19, 2024

Merger

7<1

Mar 19, 2024

Merger

7<1

Mar 19, 2024

Merger

7<1

Mar 19, 2024

Merger

7<1

Fecha

Tipo

Relación

Mar 19, 2024

Merger

7<1

Mar 19, 2024

Merger

7<1

Mar 19, 2024

Merger

7<1

Mar 19, 2024

Merger

7<1

LENZ Therapeutics Inc

29.330USD

LENZ Therapeutics Inc

29.330

Descripción general

Compañía

Finanzas